Research of incorporation of hepatic perfusion analysis using bigh-spatialresolution MRimaging

使用大空间分辨率磁共振成像进行肝脏灌注分析的研究

基本信息

  • 批准号:
    18591337
  • 负责人:
  • 金额:
    $ 1.1万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

We performed perfusion analysis of the liver after giving 5-mL gadolinium-chelate contrast material. After obtaining conventional dynamic. MR imaging of the liver, single-level cine. MR imaging was performed with 5-mL gadolinium contrast for perfusion analysis with dual-input-one-compartment model. We obtained hepatic blood flow ; hepatic, blood volume, mean transit time, and arterial-portal fraction. We evaluated if preceding dynamic MR imaging did not hamper the efficacy of subsequent perfusion imaging. We used algorithm of dual-input one-compartment model (Materne R, et. al. Magn Reson Med 2002 ; 47:135) for perfusion analysis. Several parameters derived from the analysis were correlated with clinical stages of chronic liver damage or cirrhosis, pathological stage of hepatic fibrosis, Child-Pugh score, and ICG15 test value. We found that our methodology for MR perfusion nalysis reflected the degree of hepatic fibrosis to a certain extent. We still need to solve some problems in the technical aspects to increase the accuracy of this technique.
我们在给予5 mL钆螯合物造影剂后进行肝脏灌注分析。获得常规动力后。肝脏MR成像,单水平电影。MR成像采用5 mL钆对比剂,采用双输入一室模型进行灌注分析。我们获得了肝血流量、肝血容量、平均通过时间和动脉-门静脉分数。我们评估了先前的动态MR成像是否不会妨碍后续灌注成像的有效性。我们使用双输入一室模型(Materne R,et.等人Magn Reson Med 2002 ; 47:135)用于灌注分析。分析得出的几个参数与慢性肝损伤或肝硬化的临床分期、肝纤维化的病理分期、Child-Pugh评分和ICG 15检测值相关。我们发现我们的MR灌注分析方法在一定程度上反映了肝纤维化的程度。我们还需要解决一些技术方面的问题,以提高这项技术的准确性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Classification of cirrhotic liver in gadolinium-enhanced MR images
钆增强 MR 图像中肝硬化肝脏的分类
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Lee G;Uchiyama Y;Zhang X;Kanematsu M;Zhou X;Hara T;Kato H;Kondo H;Fujita H;Hoshi H.
  • 通讯作者:
    Hoshi H.
Gadolinium-enhanced Three-dimensional MR Imaging of the Liver: Optimizing Imaging Delay for Early, Late Hepatic Arterial, and Portal Venous Phases in the Detection of Hypervascular Hepatocellular Carcinomas.
肝脏钆增强三维 MR 成像:优化富血管性肝细胞癌检测中早期、晚期肝动脉和门静脉阶段的成像延迟。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Watanabe H;Goshima S;Kondo H;Tsuge Y;Yokoyama R;Kanematsu M.
  • 通讯作者:
    Kanematsu M.
Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with MR imaging and angiographically assisted CT
  • DOI:
    10.1007/s00261-005-0091-4
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kanematsu, M;Osada, S;Moriyama, N
  • 通讯作者:
    Moriyama, N
Double hepatic arterial phase MRI of the liver with switching of reversed centric and centric K-space reordering
具有反向中心和中心 K 空间重排序切换的肝脏双肝动脉期 MRI
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kanematsu;M.;Goshima;S.;Kondo;II.;Yokoyama;R.;Kajita;K.;IIoshi;II.;Onozuka;M.;Nozaki;A.;Hirano;M.;Shiratori;Y.;Moriyama;N
  • 通讯作者:
    N
Gadolinium-enhanced multiphasic 3D MRI of the liver with prospective adaptive navigator correction: Phantom study and preliminary clinical evaluation
  • DOI:
    10.2214/ajr.06.0748
  • 发表时间:
    2007-04-01
  • 期刊:
  • 影响因子:
    5
  • 作者:
    Kanematsu, Masayuki;Goshima, Satoshi;Moriyama, Noriyuki
  • 通讯作者:
    Moriyama, Noriyuki
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KANEMATSU Masayuki其他文献

KANEMATSU Masayuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KANEMATSU Masayuki', 18)}}的其他基金

Developing a low-radiation-dose high-image-quality intelligent contrast-enhanced CT system in the era of multidetector-row CT
开发多排CT时代低辐射剂量高图像质量智能增强CT系统
  • 批准号:
    22591324
  • 财政年份:
    2010
  • 资助金额:
    $ 1.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

The role of the TIGIT immune checkpoint axis in susceptibility to infection in decompensated cirrhosis
TIGIT 免疫检查点轴在失代偿性肝硬化感染易感性中的作用
  • 批准号:
    MR/X018385/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
    Fellowship
Epigallocatechin gallate for prevention of lethal cirrhosis complications
表没食子儿茶素没食子酸酯用于预防致命性肝硬化并发症
  • 批准号:
    10713745
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
Using real-world evidence to define safe pain management strategies in cirrhosis
使用现实世界的证据来定义肝硬化的安全疼痛管理策略
  • 批准号:
    10808794
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
Investigating the role of frailty on outcomes in acutely ill patients with cirrhosis undergoing liver transplantation in the acute care setting
调查虚弱对在急症护理环境中接受肝移植的急性肝硬化患者的结局的作用
  • 批准号:
    10658726
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis
他汀类药物对肝硬化患者蛋白质组 HCC 风险特征的治疗调节
  • 批准号:
    10853142
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 1.1万
  • 项目类别:
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and Reversibility
肝硬化患者肾脏健康的新型生物标志物对急性肾损伤发生风险和可逆性的分层
  • 批准号:
    10675684
  • 财政年份:
    2022
  • 资助金额:
    $ 1.1万
  • 项目类别:
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and Reversibility
肝硬化患者肾脏健康的新型生物标志物对急性肾损伤发生风险和可逆性的分层
  • 批准号:
    10525756
  • 财政年份:
    2022
  • 资助金额:
    $ 1.1万
  • 项目类别:
Predictive models for incident cirrhosis in non-alcoholic fatty liver disease using genetic and electronic medical record-based risk factors
使用基于遗传和电子病历的危险因素对非酒精性脂肪肝病中的肝硬化事件进行预测模型
  • 批准号:
    10425053
  • 财政年份:
    2022
  • 资助金额:
    $ 1.1万
  • 项目类别:
Elucidation of the Mechanism of Regenerative Insufficiency in Advanced Liver Cirrhosis Caused by Intestinal Bacterial Extracellular Vesicles and Development of Prevention and Treatment Methods
肠道细菌细胞外囊泡所致晚期肝硬化再生不足机制的阐明及防治方法的开发
  • 批准号:
    22H02866
  • 财政年份:
    2022
  • 资助金额:
    $ 1.1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了